|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.100 CAD | -5.37% |
|
+1.76% | +20.90% |
| Jan. 02 | InnoCan Pharma to List on NYSE American Next Week | MT |
| Jan. 02 | Innocan Pharma Corp Brief: Anticipates Listing on NYSE American Stock Exchange with Concurrent Offering | MT |
Company Valuation: InnoCan Pharma Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 17.75 | 49.04 | 157.1 | 39.67 | 62.91 | 41.88 |
| Change | - | 176.32% | 220.33% | -74.75% | 58.58% | -33.43% |
| Enterprise Value (EV) 1 | 15.85 | 46.74 | 146 | 34.76 | 59.06 | 36.88 |
| Change | - | 194.95% | 212.46% | -76.2% | 69.91% | -37.55% |
| P/E ratio | -4.46x | -4.28x | -14.1x | -10.5x | -12.8x | -22.3x |
| PBR | 12.6x | -13.7x | 17.3x | 6.2x | 15.3x | 8.19x |
| PEG | - | -0x | 0.5x | 0.2x | -0.6x | 0.3x |
| Capitalization / Revenue | - | 6,129,830,384x | 801,464,590x | 15,502,550x | 4,606,416x | 1,422,662x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -5.29x | -9.98x | -19.6x | -5.58x | -15.7x | -30.4x |
| EV / EBIT | -5.28x | -9.89x | -19.5x | -5.55x | -15.5x | -29.6x |
| EV / FCF | -16.4x | 15.6x | -19.7x | -5.57x | -82x | -168x |
| FCF Yield | -6.11% | 6.41% | -5.07% | -18% | -1.22% | -0.6% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -1.797 | -3.993 | -2.908 | -0.9828 | -1.189 | -0.4257 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | 0.008 | 0.196 | 2.559 | 13.66 | 29.44 |
| EBITDA 1 | -2.998 | -4.685 | -7.437 | -6.231 | -3.77 | -1.212 |
| EBIT 1 | -3.001 | -4.725 | -7.48 | -6.266 | -3.803 | -1.247 |
| Net income 1 | -3.335 | -9.953 | -10.05 | -3.764 | -4.7 | -1.834 |
| Net Debt 1 | -1.901 | -2.3 | -11.05 | -4.913 | -3.852 | -4.998 |
| Reference price 2 | 8.018 | 17.089 | 41.091 | 10.326 | 15.258 | 9.487 |
| Nbr of stocks (in thousands) | 2,213 | 2,870 | 3,823 | 3,842 | 4,123 | 4,414 |
| Announcement Date | 4/8/20 | 3/31/21 | 3/31/22 | 3/30/23 | 4/1/24 | 3/31/25 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 26.26M | |
| 46.89x | 15.52x | 34.45x | 0.55% | 961B | |
| 21.23x | 5.89x | 16.39x | 2.36% | 527B | |
| 75.19x | 7.36x | 17.64x | 2.95% | 392B | |
| 20.01x | 5x | 12.44x | 2.87% | 368B | |
| 29.15x | 5.47x | 16.22x | 1.67% | 299B | |
| 20.36x | 5.38x | 12.6x | 2.81% | 279B | |
| 14.22x | 4.66x | 10.01x | 2.91% | 276B | |
| 16.39x | 5.8x | 11.99x | 3.08% | 262B | |
| 25.73x | 6.1x | 10.45x | 2.91% | 177B | |
| Average | 29.91x | 6.80x | 15.80x | 2.46% | 354.07B | |
| Weighted average by Cap. | 33.97x | 8.41x | 19.59x | 2.09% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- INNO Stock
- Valuation InnoCan Pharma Corporation
Select your edition
All financial news and data tailored to specific country editions
